Results 81 to 90 of about 1,385 (194)

An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease [PDF]

, 2020
BACKGROUND: Interleukin 6 (IL-6) inhibitors are the first-line treatment for idiopathic multicentric Castleman disease (iMCD); however, there is no established treatment for cases that are resistant to IL-6 inhibitors.
Bartoli, Castleman, Chan, Fajgenbaum, Herrada, Iwaki, Kawabata, Koga, Morales, Pierson, Schulz, Takada, Talat, Tedesco-Silva, World Medical, Yoshizaki   +15 more
core   +2 more sources

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling [PDF]

, 2022
BackgroundDysregulated interleukin (IL)-6 production can be characterised by the levels present, the kinetics of its rise and its inappropriate location. Rapid, excessive IL-6 production can exacerbate tissue damage in vital organs.
Bernard Klein, David C. Fajgenbaum, David C. Fajgenbaum, Frits van Rhee, Hao-Chun Chiang, Jean-François Rossi, Jean-François Rossi, Kalle Levon, Karan Kanhai, Zhao-Yang Lu   +9 more
core   +2 more sources

TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?

Biomedicines
TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis of bone marrow/renal dysfunction, organomegaly) syndrome is a systemic inflammatory disorder of unknown etiology.
Kazue Takai
doaj   +1 more source

Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series

Frontiers in Medicine, 2023
Idiopathic multicentric Castleman disease (iMCD) is a systemic and polyclonal lymphoproliferative disease involving multiple organs, including the kidneys, due to the overproduction of interleukin-6 (IL-6).
Daiki Kojima, Shintaro Yamaguchi, Akinori Hashiguchi, Kaori Hayashi, Kiyotaka Uchiyama, Norifumi Yoshimoto, Keika Adachi, Takashin Nakayama, Ken Nishioka, Takaya Tajima, Kohkichi Morimoto, Jun Yoshino, Tadashi Yoshida, Toshiaki Monkawa, Toshiaki Monkawa, Takeshi Kanda, Hiroshi Itoh   +16 more
doaj   +1 more source

Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver surveyResearch in context

EClinicalMedicine, 2023
Summary: Background: Idiopathic Multicentric Castleman Disease (iMCD) is a rare inflammatory lymphoproliferative disorder with heterogenous clinical presentations. The symptomatology in iMCD patients remains poorly understood.
Sudipto Mukherjee, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones, Nicola Mason, Matthew Franklin, John Brazier   +7 more
doaj   +1 more source

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients

Frontiers in Immunology
Introduction Idiopathic Multicentric Castleman Disease (iMCD) is a polyclonal lymphoproliferative disorder involving cytokine storms that can lead to organ failure and death. The cause of iMCD is unknown, but some clinical evidence suggests an autoimmune
A. Feng, Michael V. Gonzalez, M. Kalaycioglu, Xihui Yin, Melanie D. Mumau, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, S. E. Chang, Shaurya Dhingra, T. Dodig-Crnković, J. Schwenk, Tarun K. Garg, Kazuyuki Yoshizaki, F. van Rhee, D. Fajgenbaum, P. J. Utz   +15 more
semanticscholar   +1 more source

Interleukin‐6 transcripts up‐regulation in lymph nodes from unicentric and multicentric Castleman disease

eJHaem, Volume 5, Issue 6, Page 1182-1189, December 2024.
Abstract Introduction Castleman disease (CD) represents a spectrum of heterogeneous lymphoproliferative disorders sharing peculiar histopathological features, clinically subdivided into unicentric CD (UCD) and multicentric CD (MCD) and presenting with variable inflammatory symptoms.
Marco Lucioni, Gaia Morello, Caterina Cristinelli, Sara Fraticelli, Giuseppe Neri, Erica Travaglino, Marco Minetto, Francesca Antoci, Paolo Libretti, Marcello Gambacorta, Luca Arcaini, Claudio Tripodo, Marco Paulli   +12 more
wiley   +1 more source

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas

Blood Advances, 2018
: Castleman disease (CD) is a rare lymphoproliferative disorder subclassified as unicentric CD (UCD) or multicentric CD (MCD) based on clinical features and the distribution of enlarged lymph nodes with characteristic histopathology.
Alexandra Nagy, Aparna Bhaduri, Nahid Shahmarvand, Jahanbanoo Shahryari, James L. Zehnder, Roger A. Warnke, Tariq Mughal, Siraj Ali, Robert S. Ohgami   +8 more
doaj   +1 more source

Curative Gastrectomy for Advanced Gastric Cancer in a Patient with Idiopathic Multicentric Castleman Disease: A Rare Case Report. [PDF]

Surg Case Rep
INTRODUCTION Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and chronic immunosuppression.
Kawabata R, Ushimaru Y, Hara H, Takeoka T, Yasuhara Y, Yoshihara T, Kitagawa A, Takeda T, Tomihara H, Naito A, Murakami M, Noura S, Miyamoto A.   +12 more
europepmc   +2 more sources

Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis

European Journal of Haematology, Volume 113, Issue 6, Page 833-841, December 2024.
Abstract Background Idiopathic multicentric Castleman disease (iMCD) is a rare inflammatory disorder mediated by excessive proinflammatory cytokine signaling, most notably by interleukin 6 (IL‐6). IL‐6‐induced extramedullary hematopoiesis (EMH) has been reported in murine models of iMCD. Herein we present four cases of iMCD with EMH in humans.
Marley Blommers, Sorin Selegean, Richard K. Wood, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, E. Ashley Wiley, Emilie Comeau, Allam A. Shawwa, Stefan Rose‐John, David C. Fajgenbaum, Luke Y. C. Chen   +10 more
wiley   +1 more source